PACE-CME.org was present at ACC Scientific Sessions 2017 in Washington, DC. Follow the latest CV news here.
ACC 2017 Dr. Rob Nolan presented the results of the REACH study, in which multi-medial e-counselling significantly improved antihypertensive therapy adherence, and it lowered blood pressure.
PCSK9 Expert Opinions Prof. Gilles Lambert describes the development of PCSK9 inhibitors since the discovery in 2002 of PCSK9 as a circulating protein targeting the LDL receptor for degradation. Now in 2017, results of outcome trials with a PCSK9 inhibitor are available.
ACC 2017 Dr. P.J. Devereaux presented the VISION study, in which hs-TNT turned out to be an independent predictor of CV events and mortality around non-cardiac surgery. A post-operative peak value was determined that indicates increased risk.
PCSK9 Expert Opinions By combining all recent insights on treatment with PCSK9 inhibitors, prof. Stephen Nicholls argues that the PCSK9 outcome trials reinforce the concept that patients with high CV risk may benefit from PCSK9 inhibiting treatment.
PCSK9 Expert Opinions Dr. Paul M. Ridker states that from FOURIER and SPIRE it becomes clear that further lowering of LDL-c during a longer period of time safely translates into lower rates of CVD.
PCSK9 Expert Opinions Prof. Kausik Ray describes the practical implications of the PCSK9 outcome trials. In terms of efficacy, there is no J-shaped curve, meaning there is no apparent diminution of benefit to very low LDL
PCSK9 Expert Opinions Prof. Peter Sever describes the results of the FOURIER with respect to safety and efficacy. He puts the data into perspective of other trials and molecules.
PCSK9 Expert Opinions Prof. John Kastelein explains the most important points from FOURIER and SPIRE 1&2. He argues that there can no longer be any doubt that lowering LDL is crucial for CVD prevention.
PCSK9 Expert Opinions Prof. John Chapman gives his personal views on the results of FOURIER and SPIRE 1&2. Key question is whether in the light of the new data, the LDL-c goal will be maintained or lowered in high-CV risk individuals.
ACC 2017 AF patients starting digoxin treatment showed increased mortality, especially in the first 6 months, irrespective of the coexistence of HF, and digoxin concentrations >1.2 ng/ml should be avoided.
ACC 2017 First study investigating the effects of statins on the CNS using fMRI, showed few differences between atorvastatin 80 mg and placebo in standardised neuropsychological tests.
ACC 2017 Paroxysmal AF was associated with a higher risk of HF hospitalisation and stroke, while new-onset AF was associated with a higher risk of HF hospitalisation, death and stroke.